An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
This is an open label study designed to evaluate the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.
Advanced Solid Tumors
DRUG: ABT-806|DRUG: ABT-806i
Single-Photon Emission Computerized Tomography (SPECT), Tumor receptor occupancy (Cohort 1 and Cohort 2), Week 1|Single-Photon Emission Computerized Tomography (SPECT), Tumor receptor occupancy (Cohort 2), Week 6|Whole body planar imaging, Biodistribution and dosimetry (Cohort 1 and Cohort 2), Week 1|Whole body planar imaging, Biodistribution and dosimetry (Cohort 2), Week 6
Pharmacokinetic profile evaluation - Cohort 1, Blood samples for ABT-806/ABT-806i will be collected and assayed at designated timepoints, From Day 1 through Final Visit|Pharmacokinetic profile evaluation - Cohort 2, Blood samples for ABT-806/ABT-806i will be collected and assayed at designated timepoints, From Day 1 through Final Visit|Single-Photon Emission Computerized Tomography (SPECT), ABT-806i uptake correlation with Epidermal Growth Factor Receptor (EGFR) vIII expression - Cohort 2, Week 1|Single-Photon Emission Computerized Tomography (SPECT), ABT-806i uptake correlation with EGFR vIII expression - Cohort 2, Week 6|Whole body planar imaging, ABT-806i uptake correlation with Epidermal Growth Factor Receptor (EGFR) vIII expression - Cohort 2, Week 1|Whole body planar imaging, ABT-806i uptake correlation with EGFR vIII expression - Cohort 2, Week 6|Blood pressure - Cohort 1, Screening through Week 2|Heart rate - Cohort 1, Screening through Week 2|Body temperature - Cohort 1, Screening through Week 2|Number of subjects with Adverse Events - Cohort 1, The investigator will monitor each subject for clinical and laboratory evidence of adverse events., Day 1 Through Week 2|Chemistry - Cohort 1, Sceening, Week 1 and Final Visit|Hematology - Cohort 1, Sceening, Week 1 and Final Visit|Urinalysis - Cohort 1, Sceening, Week 1 and Final Visit|Physical Examination - Cohort 1, Physical exam including body weight will be performed., Screening, Week 1 and Final Visit|Electrocardiogram (ECG) - Cohort 1, 12-lead ECG will be performed., Baseline and Final Visit|Heart rate - Cohort 2, Screening Through Week 8|Blood pressure - Cohort 2, Screening Through Week 8|Number of subjects with Adverse Events - Cohort 2, The investigator will monitor each subject for clinical and laboratory evidence of adverse events., Day 1 Through Week 8|Body temperature - Cohort 2, Screening Through Week 8|Hematology - Cohort 2, Screening, Week 1, 2, 4, 6, and Final Visit|Chemistry - Cohort 2, Screening, Week 1, 2, 4, 6, and Final Visit|Physical Examination - Cohort 2, Physical exam including body weight will be performed., Screening, Week 1, 2, 4, 6, and Final Visit|Urinalysis - Cohort 2, Screening, Week 1, 2, 4, 6, and Final Visit|Electrocardiogram (ECG) - Cohort 2, 12-lead ECG will be performed., Baseline and Week 6
This is an open label study designed to evaluate the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.